http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CN-103087171-B
Outgoing Links
| Predicate | Object |
|---|---|
| assignee | http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_bceed6bebc0cc13575ef9690aa72e1c0 |
| classificationIPCInventive | http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-68 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-70 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07K14-46 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C12N15-13 http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/G01N33-574 |
| filingDate | 2012-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| grantDate | 2015-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| inventor | http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_b0c69dfb860f75f87c736a77ba1e410d http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_44dbc924e3c2ccc0e1603b72be844491 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_4f0ed4fc03815cde366031d5f0754897 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_afe9457f7015bd4f7ab0cda85e010eb4 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_ceaabbdeb782f344d985967be59c63f8 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_1c0a9d646b375a5f1bfe04cd4edccdb3 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_e245bd94504eb4a0df522ec9bc78d9cc http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_9cdec7d92b7f0c1dda5a58b7d202bcb1 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_50e996c6410f501747e00f9601d80082 http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_da20461986c33c602f7a6fa9c2dc4ab8 |
| publicationDate | 2015-01-14-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| publicationNumber | CN-103087171-B |
| titleOfInvention | Bispecific antibody of resisting PSMA/FITC (prostate specific membrane antigen/fluorescein isothiocyanate) for early diagnosis and treatment of prostatic cancer and preparation method of bispecific antibody |
| abstract | The invention relates to a bispecific antibody of resisting PSMA/FITC (prostate specific membrane antigen/fluorescein isothiocyanate) for early diagnosis and treatment of a prostatic cancer. A single-chain antibody about the PSMA has been reported more at present, but the bispecific antibody of resisting the PSMA/FITC is researched less. The bispecific antibody related to the invention has a full-length nucleotide sequence shown in SEQ ID No.5. The bispecific antibody is produced by a gene recombination technology, and is convenient to produce and prepare at a large scale, small in molecular weight of an antibody, and strong in penetrating power of tumor tissue; micromolecule antibody can easily achieve the diseased region aiming at the anatomical features that the prostate tissue has thick prostate envelope; and treatment and early diagnosis of the prostatic cancer can be achieved by drugs carried by hapten or a marker by combining with prostatic cancer cells of the diseased region by a pre-targeting technology. |
| priorityDate | 2012-12-24-04:00^^<http://www.w3.org/2001/XMLSchema#date> |
| type | http://data.epo.org/linked-data/def/patent/Publication |
Incoming Links
Total number of triples: 63.